Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 23.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 533,324 shares of the company’s stock after purchasing an additional 102,715 shares during the quarter. BNP Paribas Financial Markets owned about 0.53% of Neurocrine Biosciences worth $61,450,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Quantbot Technologies LP acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter worth approximately $89,000. Qsemble Capital Management LP acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter worth approximately $1,238,000. Bank of Montreal Can lifted its holdings in shares of Neurocrine Biosciences by 40.4% in the 3rd quarter. Bank of Montreal Can now owns 55,244 shares of the company’s stock worth $6,356,000 after acquiring an additional 15,893 shares during the last quarter. Truvestments Capital LLC purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $63,000. Finally, Fisher Asset Management LLC increased its stake in Neurocrine Biosciences by 7.8% during the 3rd quarter. Fisher Asset Management LLC now owns 68,270 shares of the company’s stock worth $7,866,000 after buying an additional 4,930 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NBIX has been the topic of several recent research reports. Jefferies Financial Group upped their target price on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Guggenheim upped their target price on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Royal Bank of Canada cut their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. Finally, Raymond James reaffirmed an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Five equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $126.59 on Thursday. The firm’s fifty day moving average price is $118.97 and its 200 day moving average price is $131.71. The company has a market capitalization of $12.82 billion, a price-to-earnings ratio of 33.94 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12 month low of $110.81 and a 12 month high of $157.98.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.